Journal September 18, 2026 7 min read

BPC-157 vs GHK-Cu: What the Research Actually Compares

A side-by-side look at the published literature on BPC-157 and GHK-Cu: what each compound is, what studies measured, where the evidence is denser, and where it runs out.

peptides-pro Editorial

BPC-157 is a synthetic pentadecapeptide (body protection compound 157) derived from a fragment of a gastric protein; it is also referred to in the literature as BPC 157 or Body Protective Compound-157 [6][8]. GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, written in the literature as Glycyl-L-histidyl-L-lysine copper(II) or GHK-Cu [3][9]. The two are not members of the same structural class: one is a fifteen-residue peptide, the other a three-residue peptide bound to a copper ion, and the published work on each centres on different mechanistic questions.

For BPC-157, the work centres on cytoprotective, angiogenic and anti-inflammatory signalling, including nitric oxide pathway modulation and, in a separate line of enquiry, acetylcholinesterase inhibition [4][8]. For GHK-Cu, the work centres on copper-dependent catalytic and antioxidant behaviour, keratinocyte and fibroblast responses, and cytokine modulation in skin and neural models [3][5][7].

Research Studies

BPC-157 and tendon healing in a surgical human model

The only formal human trial design identified in the evidence for BPC-157 is a randomized, double-blind, placebo-controlled pilot study in patients undergoing arthroscopic rotator cuff repair [1]. Twenty patients are to be enrolled and assigned to BPC-157 or saline placebo, with daily subcutaneous self-administration for 90 days after surgery, alongside standard postoperative care [1]. The record notes that BPC-157 has shown regenerative and anti-inflammatory effects in preclinical animal models of musculoskeletal injury but had not previously been studied in formal human clinical trials [1]. This is a registered protocol; the evidence block does not report outcomes.

BPC-157 and tendon healing in a rat model

A rat study evaluated BPC-157, synthetic thymosin beta-4 (TB-500), and their combination in Achilles tendon healing, using biomechanical, histopathological, histochemical and immunohistochemical analyses in thirty-two male Sprague-Dawley animals [11]. The design places BPC-157 within a comparative tendon-repair model rather than a single-compound test.

BPC-157 and acetylcholinesterase inhibition

BPC-157 and two rationally designed hybrid analogs, CIARA-1 and CIARA-2, were tested for acetylcholinesterase inhibitory potential [4]. The hybrids combined a BPC-157-derived fragment with an arginine-containing C-terminal sequence intended to improve interactions with the enzyme's active and peripheral binding sites; kinetics were assessed with a modified Ellman assay and Lineweaver-Burk analysis [4]. This is an in vitro enzyme-kinetics line of work, distinct from the tissue-repair literature.

BPC-157 and tissue repair across preclinical models

A review of the BPC-157 literature reports that experimental evidence supports angiogenesis, collagen synthesis, fibroblast activity and modulation of nitric oxide pathways, contributing to healing of muscle, tendon, ligament, bone and gastrointestinal tissue [8]. The same review reports reduced inflammatory cytokine activity, improved microvascular integrity, and effects on pain modulation through peripheral and dopaminergic mechanisms in animal data [8].

BPC-157 and formulation or translational barriers

A biopharmaceutical review describes BPC-157 as having over three decades of preclinical research showing consistent biological activity, while noting that pharmaceutical development remains rudimentary, with no approved formulation, no validated dosing regimen, and no completed Phase II clinical trial [6]. The review examines physicochemical and pharmacokinetic properties and formulation challenges across routes of administration [6]. A separate materials study fabricated and characterized a chitosan/BPC-157 composite hydrogel, reporting a porous structure analysed by scanning electron and transmission electron microscopy [12].

GHK-Cu and circulating levels in healthy adults

A two-part clinical trial protocol investigates GHK and GHK-Cu blood levels before and after intervention in healthy adults, and the efficacy of an X39 patch compared with placebo patches [2]. The stated questions are the change in GHK and GHK-Cu levels from baseline to Day 8, and the difference in that change between patch and placebo [2]. Participants complete a questionnaire and use the patch [2]. As with the BPC-157 surgical protocol, this is a registered design; the evidence block does not report results.

GHK-Cu and keratinocyte recovery in an atopic dermatitis model

A complex of Torilis japonica extract and GHK-Cu was formulated and examined for anti-atopic and skin-regenerative properties using a TNF-α-stimulated model, in work framed around Th2 cytokine attenuation, oxidative stress and epidermal barrier defects in atopic dermatitis [3]. The study reports attenuation of Th2 cytokines and promotion of keratinocyte recovery [3]. The test article is the extract–GHK-Cu complex, not GHK-Cu alone.

GHK-Cu and hippocampal aging in middle-aged mice

Middle-aged mice treated with GHK-Cu administered intraperitoneally or intranasally showed behavioural rescue but divergent hippocampal aging programs, according to the study title and record [5]. The route of administration is a variable in the design, and the reported outcome differs by route.

GHK-Cu and laccase-like catalytic activity

GHK-Cu was reported to possess laccase-like properties, with a Vmax of 1.735 × 10^-4 mM·s^-1 and a Km of 0.061 mM, indicating substrate affinity and catalytic efficiency [7]. A colorimetric method was then developed for detection of epinephrine and 2-aminophenol, with a linear response range of 20–240 μM and a limit of detection of 9.5 μM for epinephrine, and linear ranges of 14–100 μM for 2-aminophenol [7]. This is an analytical-chemistry application of the copper centre.

GHK-Cu and skin or cosmetic formulations

Reference work reports that GHK-Cu has demonstrated regenerative, anti-inflammatory and antioxidant properties in preclinical models, which has prompted its increasing integration into aesthetic medicine [9]. A further study examined augmented skin-beneficial effects of a Thermus thermophilus and Bacillus subtilis mixed-culture ferment extract combined with the tripeptide GHK-Cu, in a formulation targeting multiple skin-aging pathways simultaneously [10].

Where the two literatures differ

Dimension	BPC-157	GHK-Cu
Structural class	Synthetic pentadecapeptide from a gastric protein fragment [6][8]	Copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine [3][9]
Human trial record in this evidence	One registered randomized, double-blind, placebo-controlled pilot protocol in rotator cuff repair; no outcomes reported [1]	One registered two-part protocol measuring circulating GHK/GHK-Cu in healthy adults; no outcomes reported [2]
Animal model data	Achilles tendon healing in rats, comparative with TB-500 [11]; broad preclinical tissue-repair review [8]	Middle-aged mice, intraperitoneal and intranasal routes, hippocampal outcomes [5]
In vitro / mechanistic data	Acetylcholinesterase inhibition kinetics with hybrid analogs [4]	Laccase-like kinetics and colorimetric sensing [7]
Formulation science	Chitosan/BPC-157 hydrogel characterization [12]; formulation and translational barriers reviewed [6]	Extract–GHK-Cu complex in a TNF-α-stimulated skin model [3]; ferment extract plus GHK-Cu formulation [10]
Development status noted	No approved formulation, no validated dosing regimen, no completed Phase II trial [6]	Not characterized in this evidence block

The evidence does not support declaring one compound the better-studied or better-supported agent overall. What it supports is narrower: BPC-157 has a longer and broader preclinical tissue-repair record, including a tendon model and a review of healing across muscle, tendon, ligament, bone and gastrointestinal tissue [8][11], plus an explicit statement that its pharmaceutical development remains rudimentary [6]. GHK-Cu's evidence in this block is weighted toward skin biology, catalytic chemistry and a single mouse neurobehavioural study, with a human protocol limited to measuring circulating levels rather than clinical endpoints [2][3][5][7].

What is simply not known, on this evidence: whether BPC-157 improves tendon healing or functional recovery in humans, because the rotator cuff protocol has no reported outcomes [1]; whether GHK-Cu patch use changes circulating GHK-Cu levels relative to placebo, for the same reason [2]; how either compound performs against the other in any shared model, since no head-to-head study appears in the evidence block; and what human dosing, if any, corresponds to the exposures used in the animal and in vitro work [6].

If you are reading this for personal health reasons

The materials described here are sold for laboratory research use only. We do not provide dosing, administration or medical guidance of any kind. Anyone considering a compound for themselves should speak to a licensed clinician.